413 related articles for article (PubMed ID: 25416723)
1. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
[TBL] [Abstract][Full Text] [Related]
3. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
Dillard T; Yedinak CG; Alumkal J; Fleseriu M
Pituitary; 2010; 13(1):29-38. PubMed ID: 19639414
[TBL] [Abstract][Full Text] [Related]
4. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-induced hypophysitis: review of the literature.
Araujo PB; Coelho MC; Arruda M; Gadelha MR; Neto LV
J Endocrinol Invest; 2015 Nov; 38(11):1159-66. PubMed ID: 25957829
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
7. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
[TBL] [Abstract][Full Text] [Related]
8. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
Iwama S; De Remigis A; Callahan MK; Slovin SF; Wolchok JD; Caturegli P
Sci Transl Med; 2014 Apr; 6(230):230ra45. PubMed ID: 24695685
[TBL] [Abstract][Full Text] [Related]
9. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy.
Lammert A; Schneider HJ; Bergmann T; Benck U; Krämer BK; Gärtner R; Metzner C; Schöfl C; Berking C
Exp Clin Endocrinol Diabetes; 2013 Nov; 121(10):581-7. PubMed ID: 24122241
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
[TBL] [Abstract][Full Text] [Related]
11. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease.
Torino F; Barnabei A; De Vecchis L; Salvatori R; Corsello SM
Oncologist; 2012; 17(4):525-35. PubMed ID: 22477725
[TBL] [Abstract][Full Text] [Related]
12. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis.
Heaney AP; Sumerel B; Rajalingam R; Bergsneider M; Yong WH; Liau LM
J Clin Endocrinol Metab; 2015 Nov; 100(11):4092-7. PubMed ID: 26317559
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case.
Marques P; Grossman A
Acta Med Port; 2015; 28(6):775-9. PubMed ID: 27265913
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
[TBL] [Abstract][Full Text] [Related]
15. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
Kaehler KC; Egberts F; Lorigan P; Hauschild A
Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
[TBL] [Abstract][Full Text] [Related]
16. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
van der Hiel B; Blank CU; Haanen JB; Stokkel MP
Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
[TBL] [Abstract][Full Text] [Related]
17. [Ipilimumab-induced hypophysitis].
Schleder S; Schreml S; Heiss P
Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
[No Abstract] [Full Text] [Related]
18. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
20. MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis.
Albarel F; Castinetti F; Brue T
Eur J Endocrinol; 2019 Sep; 181(3):R107-R118. PubMed ID: 31311002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
